|
EQS-News: Medios AG
/ Key word(s): Preliminary Results/9 Month figures
Press release Medios AG: Strong operating cash flow – record figures as expected also for revenue and earnings in the third quarter of 2023 Financials Q3 2023 vs. Q3 2022:
Berlin, October 24, 2023 – Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, again grew strongly in the third quarter of 2023, as expected. Based on preliminary and unaudited figures (IFRS), revenue in the third quarter amounted to around €489.9 million (+16.9% vs. Q3 2022) and EBITDA pre1 to around €17.2 million (+12.2% vs. Q3 2022). These figures are slightly above the current analyst consensus for Q3 2023 (revenue: €455.4 million; EBITDA pre1: €16.0 million). Cash flow from operating activities amounted to €86.0 million in the third quarter (previous year: €7.9 million) resulting from the sale of inventories strategically built up in the first half of the year. In the period from January to September 2023, revenue increased by 10.9% to €1,343.5 million (previous year: €1,211.4 million) according to preliminary figures. Medios achieved a preliminary EBITDA pre1 increase of 5.5% to €46.3 million (previous year: €43.8 million) in the same period. These figures are also slightly above the current analyst consensus for the nine-month period 2023 (revenue: €1,308.7 million; EBITDA pre1: €45.0 million). Matthias Gaertner, CEO of Medios AG: "We proudly look back on the best quarter in the history of Medios AG so far – with a high increase in revenue, a significant increase in earnings and a particularly strong operating cash flow. I am very pleased that together as a team we were once again able to achieve such great success – and this in these generally challenging times.” Medios will publish the full Quarterly Statement as of September 30, 2023, on November 14, 2023. Important dates for Medios AG in the 2023 financial year: November 14: Quarterly Statement (Q3 and 9M 2023) November 30: CIC Market Solutions Forum – Paris December 06: Berenberg European Conference – Pennyhill 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjusted for special charges for stock options and expenses for M&A activities as well as from 2023 additionally for one-time performance-based payments for the acquisition of compounding volumes. ------------------- About Medios AG Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies. Medios AG is Germany's first listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard). Contact Anna Höffken
Disclaimer This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.
24.10.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Medios AG |
| Heidestraße 9 | |
| 10557 Berlin | |
| Germany | |
| Phone: | +49 30 232 566 - 800 |
| Fax: | +49 30 232 566 - 801 |
| E-mail: | ir@medios.ag |
| Internet: | www.medios.ag |
| ISIN: | DE000A1MMCC8 |
| WKN: | A1MMCC |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1755991 |
| End of News | EQS News Service |
|
|
1755991 24.10.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
